Polymorphisms in the B-type natriuretic peptide (BNP) gene are associated with NT-proBNP levels but not with diabetic nephropathy or mortality in type 1 diabetic patients

Nephrology Dialysis Transplantation

Volumn 22, Issue 11, 2007, Pages 3235-3239

  Lajer, Maria ^a   Tarnow, Lise ^a   Jorsal, Anders ^a   Parving, Hans Henrik ^b,c  

^a STENO DIABETES CENTER   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c Rigshospitalet   (Denmark)

Author keywords

BNP; Diabetic nephropathy; N terminal pro B type natriuretic peptide; Polymorphism; Type 1 diabetes

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; DNA;

ADULT; ALBUMINURIA; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CAUCASIAN; CIRCULATION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE DURATION; DNA POLYMORPHISM; FEMALE; FOLLOW UP; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENOTYPE; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOASSAY; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL;

ADULT; BODY MASS INDEX; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; POLYMORPHISM, GENETIC;

EID: 36749011359     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm360     Document Type: Article

References (17)

1. Parving H-H. Renoprotection in diabetes: genetic and nongenetic risk factors and treatment. Diabetologia 1998; 41: 745-759
2. De Lemos JA, Morrow DA, Bentley JH et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Eng J Med 2001; 345: 1014-1021
3. Luchner A, Hengstenberg C, Löwel H, Riegger GA, Schunkert H, Holmer S. Effect of compensated renal dysfunction on approved heart failure markers: direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP. Hypertension 2005; 46: 118-123
4. Gardner RS, Ozalp F, Murday AJ, Robb SD, McDonagh TA. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 2003; 24: 1735-1743
5. Olsen MH, Wachtell K, Tuxen C et al. N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study. J Hypertens 2004; 22: 1597-1604
6. Madsen LH, Ladefoged S, Corell P, Schou M, Hildebrandt PR, Atar D. N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis. Kidney Int 2007; 71: 548-554
7. Tarnow L, Hildebrandt P, Hansen BV, Borch-Johnsen K, Parving H-H. Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy. Diabetologia 2005; 48: 149-155
8. Gaede P, Hildebrandt P, Hess G, Parving H-H, Pedersen O. Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Diabetologia 2005; 48: 156-163
9. Tarnow L, Gall MA, Hansen BV, Parving H-H. Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes. Diabetologia 2006; 49: 2256-2262
10. Tarnow L, Cambien F, Rossing P et al. Insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene is associated with coronary heart disease in IDDM patients with diabetic nephropathy. Diabetologia 1995; 38: 798-803
11. National Kidney Foundation: K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease. Evaluation, Classification, and Stratification. Am J Kidney Dis 2002; 39: S1-S266
12. Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. The Lancet 2003; 362: 759-766
13. Andersen NH, Poulsen SH, Knudsen ST, Heickendorff L, Mogensen CE. NT-proBNP in normoalbuminuric patients with Type 2 diabetes mellitus. Diabetic Med 2005; 22: 188-195
14. Epshteyn V, Morrison K, Krishnaswamy P et al. Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. Diabetes Care 2003; 26: 2081-2087
15. Gaede P, Hildebrandt P, Hess G, Parving HH, Pedersen O. Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Diabetologia 2005; 48: 156-163
16. Sekido R, Murai K, Funahashi JI et al. The delta;-crystallin enhancer-binding protein deltaEF1 is a repressor of E2- box-mediated gene activation. Mol cell Biol 1994; 14: 5692-5700
17. Onuoha GN, Nicholls DP, Patterson A, Beringer T. Neuropeptide secretion in exercise. Neuropeptides 1998; 32: 319-325